A Phase I/II Safety, Tolerability, and 'Proof of Concept' Study of TNFerade Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2012
At a glance
- Drugs Golnerminogene pradenovec (Primary) ; Fluorouracil; Hydroxycarbamide
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TNF-CORE
- Sponsors GenVec
- 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jun 2008 Encouraging interim data presented at ASCO 2008.